Switzerland · Delayed Price · Currency is CHF Basilea Pharmaceutica AG Earnings Call Transcripts
Fiscal Year 2025
-
2025 saw robust revenue and profit growth, driven by Cresemba's global momentum and Zevtera's U.S. launch. The pipeline expanded with new phase 3 assets, and significant non-dilutive funding was secured, positioning for sustained growth despite upcoming generic competition for Cresemba.
-
Strong H1 2025 results driven by Cresemba's robust sales and Zevtera's U.S. launch, with total revenue up 36% year-on-year. Pipeline expanded with a new oral antibiotic, and 2025 guidance raised for revenue and operating profit, despite expected product revenue decline from Pfizer supply.
Fiscal Year 2024
-
Strong 2024 results featured a tripling of operating profit and robust revenue growth, driven by Cresemba and Zevtera. The pipeline expanded with new antifungal and antibiotic assets, and significant non-dilutive funding was secured. 2025 guidance anticipates continued revenue and profit growth.
-
Strong H1 2024 results driven by Cresemba growth and Zevtera U.S. approval led to raised full-year guidance. Pipeline expanded with four new anti-infective programs, and significant milestone payments are expected in H2. Debt reduction and stable expenses support a positive outlook.